Active Targeting with Carbohydrate Ligands: A Practical Guide for High-Precision Drug Delivery

Active targeting with carbohydrate ligands directs carriers to the right cells through precise sugar–receptor recognition. This article outlines key receptors, design knobs, and carrier choices you can apply now. It also introduces how Creative Biolabs can support fast prototyping and rigorous QC for research-only delivery.

What Is Active Targeting with Carbohydrate Ligands?

Compared with traditional cancer treatments, which often cause severe systemic toxicity due to their inability to distinguish between tumor and normal cells, targeted drug delivery systems have emerged as a transformative solution. Among these, active targeting with carbohydrate ligands stands out for its precision, biocompatibility, and reliance on natural biological interactions. Active targeting with carbohydrate ligands leverages specific, receptor-mediated binding to direct therapeutic cargos exclusively to diseased cells, minimizing off-target damage.

Carbohydrates, including monosaccharides (e.g., glucose, galactose), disaccharides (e.g., lactobionic acid), and polysaccharides (e.g., hyaluronic acid, HA), are ideal targeting ligands for several reasons (Figure 1). Firstly, their biocompatibility and non-immunogenicity enable them to exhibit reduced risks of adverse immune responses. Second, cancer cells have an increased demand for carbohydrates to fuel their rapid growth (Warburg effect). This means that carbohydrate-specific receptors are often overexpressed on their surface, e.g., glucose transporters (GLUT1) for glucose, asialoglycoprotein receptors (ASGPR) for galactose, and CD44 receptors for HA. The "biological address" of the overexpressed receptors can be recognized by the carbohydrate-modified drug carriers, allowing binding of the targeting ligand on the drug carrier to its cognate receptor. This binding leads to receptor-mediated endocytosis of the ligand-drug conjugates, facilitating intracellular drug delivery. For example, HA-conjugated NPs have been shown to be easily accumulated in CD44-overexpressing breast, colon, and liver tumors, which could improve therapeutic efficacy and reduce toxicity to normal tissues. These ligand-receptor interactions can be responsive to the tumor microenvironment, such as acidic pH or certain enzymes, for more optimal therapeutic effects.

Fig.1 Active targeting with carbohydrate ligands.³

As a core component of high-precision drug delivery, active targeting with carbohydrate ligands bridges natural biological processes with nanomedical innovation. In this practical guide, Creative Biolabs will break down the key principles, common carbohydrate ligands, and real-world applications of active targeting with carbohydrate ligands, equipping researchers and clinicians to harness their potential for more effective and safer cancer therapy.

● For more information related to the active targeting services, please visit Targeting Module Development Services.

How Carbohydrate Ligand Works (Step-by-Step)

Active targeting with carbohydrate ligands relies on a sequential, receptor-mediated process that ensures precise delivery of therapeutic cargos to tumor cells.

Step 1: Ligand-Receptor Recognition

As mentioned in the introduction, specific carbohydrate-binding receptors are overexpressed by tumor cells, such as asialoglycoprotein receptors (ASGPR) in hepatocellular carcinoma cells, and CD44 receptors in colon cancer cells. Carbohydrate ligands (e.g., HA, galactose, glucose) conjugated to drugs or drug carriers (e.g., nanoparticles, NPs) can circulate in the bloodstream and selectively recognize these overexpressed receptors, forming stable ligand-receptor complexes.

Step 2: Receptor-Mediated Endocytosis

Binding initiates endocytosis, where the tumor cell membrane invaginates and forms vesicles (endosomes) around the ligand-conjugated carrier. For instance, HA-modified NPs can bind to CD44 on MDA-MB-231 breast cancer cells, prompting clathrin-mediated endocytosis that pulls the NPs into the cells. This step ensures these carriers are internalized by receptor-overexpressing tumor cells while avoiding uptake by normal cells with low receptor expression.

Step 3: Tumor Microenvironment-Triggered Cargo Release

Endosomes containing the carrier then fuse with lysosomes, and the therapeutic cargo is triggered to release by the acidic tumor microenvironment (pH 5.0-6.5) or tumor-specific enzymes (e.g., hyaluronidase for HA). A typical example of this is the doxorubicin (DOX)-loaded NPs conjugated with lactobionic acid (LA), which can target HepG2 liver cancer cells by binding the LA to the ASGPR in HepG2 liver cancer cells and releasing DOX after endosomal acidification. NPs conjugated with HA can release encapsulated drugs in CD44⁺ tumor cells by degradation by hyaluronidase. The stimuli-responsive release ensures that the drug is released directly within tumor cells, thereby maximizing drug efficacy.

Step 4: Fate of Carrier and Ligand

The carbohydrate ligands and carriers are finally biodegraded and cleared safely after the release of the drug. The whole process, which is initiated by tumor-specific receptors and further driven by the tumor microenvironment, causes no harm to normal cells with negligible receptor expression and neutral pH. In this manner, systemic toxicity can be dramatically reduced compared to conventional chemotherapy.

Receptor-Ligand Map for Carbohydrate Ligands

Table 1 distills core insights for carbohydrate-mediated active targeting. It includes four common receptor-ligand pairs, each associated with a typical tumor-specific receptor, its corresponding carbohydrate ligand, and common carriers. It also highlights critical processes, such as clathrin-mediated endocytosis and stimuli-responsive release, ensuring precise drug delivery to tumors while cutting off-target toxicity.

Table 1: Receptor-Ligand MAP for carbohydrate ligands.

Start a ligand selection sprint or request a prototype package today. Visit our Targeted Delivery hub and Targeting Module Development Services to get started.

Design Knobs That Drive Performance

Ligand Density and Multivalency

Ligand density and multivalency are key to boosting targeting affinity. Too low ligand density causes weak receptor binding, while overly high ligand density may induce steric hindrance. By utilizing the cluster glycoside effect, multivalent carbohydrate clusters (e.g., multiple galactose moieties on a single carrier) can enhance affinity for receptors such as ASGPR and outperform single-ligand carriers.

Linker Chemistry & Spacer Length

Linker chemistry controls the stability between the ligand and the carrier, while spacer length determines accessibility. Common methods, such as EDC/NHS coupling, are widely used for HA/LA conjugation to nanoparticles. Proper spacer length can prevent shielding and allow the ligand to bind freely. For instance, PEG can help present ligands beyond the protein corona as a spacer.

Orientation & Presentation

Correct ligand orientation guarantees effective receptor binding, as site-selective coupling reduces random orientations. Therefore, proper ligand orientation is critical for receptor recognition. For example, mannose ligands must present their hydroxyl groups in a specific configuration to match mannose receptors; otherwise, the misoriented counterpart (e.g., a flipped mannose on silica NPs) can drastically reduce tumor cell uptake, even at high density.

Particle Size, Charge, and Corona

The particle size of the drug-loaded carriers can influence in vivo circulation and tissue penetration: larger ones can become trapped in blood vessels, while smaller ones can be cleared rapidly. Normally, Particles with diameters of 10–200 nm can balance circulation time and tumor penetration, enabling them to penetrate tumors before being cleared. Moreover, a mild negative charge (e.g., HA-coated NPs) can prevent rapid liver uptake, and stealth coatings (e.g., PEG modification) can mitigate protein corona formation, thereby shielding ligands from receptors.

Payload Release Logic

Payload release is tuned to tumor microenvironment cues. pH-sensitive, redox-responsive, and enzyme-cleavable designs ensure the payload is released after endocytosis. For example, acidic endosomal pH (5.0-6.5) can break acid-sensitive linkers, thus releasing drugs such as DOX from LA-conjugated NPs. Hyaluronidase-cleavable HA linkers can ensure site-specific cargo release exclusively in CD44⁺ tumor cells.

Carrier Options for Carbohydrate-Directed Targeting

Lipid nanoparticles (LNPs)

Lipid nanoparticles (LNPs) are lipid-based carriers well-suited for carbohydrate-directed targeting. Carbohydrate-decorated LNPs are typically composed of a lipid core (e.g., solid lipids like stearic acid) and a surface layer modified with carbohydrates. They excel at encapsulating both hydrophobic and hydrophilic drugs, such as chemotherapeutics or phototherapeutic agents, while displaying ligands such as lactobionic acid (LA) or galactose on their surfaces. These surface modifications can then facilitate the binding of the LNPs to specific receptors (e.g., asialoglycoprotein receptors (ASGPR) on liver cancer cells), which aids in selective tumor targeting. In addition, LNPs also provide good biocompatibility, low immunogenicity, and can be easily scaled up for production, all of which are important for translation into clinical applications.

Polymeric nanoparticles/micelles

These carriers can be easily conjugated with carbohydrates. For instance, polymeric micelles modified with HA can bind to CD44 receptors overexpressed on breast, colon, and liver tumor cells, enabling receptor-mediated endocytosis. They also offer high drug-loading capacity and can be designed for stimuli-responsive release, including acid-triggered drug release in the acidic tumor microenvironment (pH 5.0-6.5) or enzyme-triggered release via hyaluronidase, thereby ensuring release of cargo exclusively at the target site.

Liposomes

Liposomes are structurally an aqueous core surrounded by lipid bilayers, allowing them to encapsulate both water-soluble drugs (in the core) and lipid-soluble drugs (in the bilayer). To enable carbohydrate-directed targeting, liposomes can be decorated with ligands such as galactose, LA, or HA on their outer bilayer. For example, galactose-decorated liposomes can specifically target ASGPR on hepatocellular carcinoma cells, and HA-coated liposomes can bind to CD44 receptors on multiple tumor types.

Dendrimers and precision scaffolds

Dendrimers and precision scaffolds are highly structured, branched carriers. They have a well-controlled carbohydrate presentation, which is essential for carbohydrate-directed targeting. Dendrimers (e.g., polyamidoamine, PAMAM) possess a well-defined, spherical structure with multiple surface functional groups, enabling uniform conjugation of carbohydrates such as glucose or mannose. The uniform ligand density can lead to the consistent binding of various receptors, such as GLUT1 (a glucose receptor) on lung cancer cells or mannose receptors (MR) on TAMs. Precision scaffolds are another well-defined, branched carrier often made from synthetic polymers with a defined architecture. These platforms can also allow for well-controlled placement of carbohydrate ligands to avoid steric hindrance and can be used to investigate key aspects of multivalent recognition. Beyond targeting, these carriers support co-delivery of multiple payloads, such as chemotherapeutic drugs and imaging agents, making them useful for theranostic applications (simultaneous diagnosis and therapy). Their predictable structure also simplifies optimization of ligand density and carrier size, ensuring reliable performance in carbohydrate-directed targeting.

Small-molecule or polymer conjugates

Small molecule or polymer conjugates can directly link carbohydrates to therapeutic agents or polymer backbones, thus eliminating the need for a separate nanoparticle carrier and reducing carrier-related toxicity. In small-molecule conjugates, carbohydrates such as glucose and galactose are covalently linked to cytotoxic drugs such as chlorambucil and methotrexate via stable linkers. These conjugates can be taken up by tumor cells through carbohydrate receptors, such as GLUT1 and ASGPR, for glucose and galactose, respectively. In polymer conjugates, the carbohydrates are attached to the biocompatible polymer carrier, such as HA or polyethylene glycol, that has a drug conjugated to it. For example, HA-doxorubicin polymer conjugates can target CD44 receptors on breast cancer cells, where HA serves not only as a targeting ligand but also enhances the water solubility of the drug. Both types of conjugates rely on receptor-mediated endocytosis for intracellular delivery, and their linkers can be designed to release the drug only in the tumor microenvironment.

For platform planning, see Targeting Module Development Services at Creative Biolabs and the Targeted Delivery hub.

Biomedical Applications of Carbohydrate Ligands

Table 2 distills key applications of carbohydrate ligand-targeted active targeting, linking five critical application areas to their target molecules, matching carbohydrate ligands, and tailored carriers/payloads. It simplifies how ligands such as lactobionic acid (liver), hyaluronic acid (CD44⁺ tumors), and mannose (immune cells) drive precise delivery for chemotherapy, immunomodulation, gene editing, and treating inflammation/infection.

Table 2: Biomedical Applications of carbohydrate ligands.

Challenges and Solutions

This section presents a discussion of the challenges associated with implementing active targeting via carbohydrate ligands, along with potential workable solutions.

Challenge 1: Shielding of Ligands by Protein Corona

Description: The protein corona is a coating formed on a carrier when it interacts with blood proteins. Carbohydrate ligands can be shielded by the protein corona, thereby precluding their binding to target receptors and diminishing targeting efficacy.

Solution: Stealth coatings (e.g., PEGylation) or zwitterionic modifications can be applied to the carrier. The stealth layer is expected to repel the nonspecific adsorption of proteins, thereby sparing the ligands.

Challenge 2: Poor Ligand-Receptor Affinity with Low Receptor Expression

Description: Tumors with low levels of receptors (e.g., early-stage liver cancer may have low ASGPR expression) often have very poor binding to a single carbohydrate ligand and therefore inadequate carrier uptake.

Solution: The presentation of multivalent ligands, an approach that involves the coupling of multiple carbohydrate moieties (e.g., galactose clusters) to a single carrier, could be employed. The "cluster glycoside effect" which ensues from this approach increases the binding affinity of ligands to target receptors even at low receptor densities.

Challenge 3: Off-Target Uptake by Healthy Tissues

Description: Some receptors (e.g., mannose receptors on normal macrophages) are expressed on healthy cells, causing unintended carrier accumulation and potential toxicity.

Solution: Carbohydrate targeting could be combined with tumor microenvironment (TME) stimuli in the design. For example, design mannose-conjugated carriers with acid-sensitive linkers. As a result, these drug-loaded carriers bind to mannose receptors on both healthy and tumor-associated macrophages (TAMs) but only release payloads in the acidic TME (pH 5.0-6.5).

Challenge 4: Limited Penetration of Large Carriers into Tumor Parenchyma

Description: Carriers larger than 200 nm in diameter struggle to penetrate beyond tumor blood vessels, as they remain trapped in the extracellular matrix.

Solution: Carrier size (10-100 nm) should be optimized, and flexible polymers (e.g., HA-based micelles) should be utilized. Smaller, flexible carriers tend to navigate the tumor matrix more easily.

Challenge 5: Instability of Ligand-Carrier Conjugates in Circulation

Description: Hydrolytic or enzymatic cleavage of the carbohydrate-carrier bond may release ligands before they reach the target.

Solution: Biorthogonal, stable conjugation chemistries (e.g., click chemistry or amide bond formation with steric protection from hydrolysis) must be used. Click chemistry-based conjugation of glucose to dendrimers has been shown to be resistant to serum enzyme-mediated hydrolysis, preserving the ligand during circulation.

How Creative Biolabs Helps (Buyer-Centric)

Our End-to-End Workflow

1. Target receptor & ligand selection: Literature scan, glycan microarray guidance, and receptor-expression rationale.
2. Carrier & conjugation strategy: Choose LNP, liposome, polymer, or conjugate; fix ligand density, linker, and orientation.
3. Rapid prototyping: Prepare small batches to confirm size, PDI, zeta potential, and ligand display.
4. In vitro binding and uptake: Flow cytometry, confocal microscopy, and optional BLI/SPR as needed.
5. Stability & release profiling: pH/redox/enzymatic triggers; serum stability; release kinetics.
6. Scale-up feasibility: Map process parameters and provide a path to larger batches and technical transfer.

Deliverables You Receive

• Formulation specifications: Composition, ligand ratio, and physical attributes.
• QC package: Particle size, PDI, zeta, ligand display confirmation, and stability.
• Targeting evidence: Binding/uptake study summary and key images.
• Recommendations: Next-step design knobs and risk-reduction tips.

For Research Use Only. Not For Clinical Use.

Related Services You May Be Interested in

FAQs

References

1. Shanina, E. et al. "Targeting undruggable carbohydrate recognition sites through focused fragment library design." Commun Chem 5, 64 (2022). https://www.nature.com/articles/s42004-022-00679-3.
2. Wang, J., Zhang, Y., Lu, Q., Xing, D. & Zhang, R. "Exploring Carbohydrates for Therapeutics: A Review on Future Directions." Front. Pharmacol. 12, 756724 (2021). https://www.frontiersin.org/articles/10.3389/fphar.2021.756724/full.
3. Yan, S., Na, J., Liu, X. & Wu, P. "Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy." Pharmaceutics 16, 248 (2024). https://www mdpi.com/1999-4923/16/2/248. Distributed under Open Access license CC BY 4.0, without modification.